The adenosine A3 receptor agonist, N6-(3-iodobenzyl)-adenosine-5′-N-methyluronamide, is protective in two murine models of colitis

Add time:07/14/2019    Source:sciencedirect.com

This study evaluated the effects of the adenosine A3 receptor agonist, N6-(3-iodobenzyl)-adenosine-5′-N-methyluronamide (IB-MECA), in two murine models of colitis, the dextran sodium sulphate-induced colitis and the spontaneous colitis found in interleukin-10 gene deficient mice. IB-MECA was given orally twice a day at a dose of either 1 or 3 mg/kg/day. Evaluation of colon damage and inflammation was determined grossly (body weight, rectal bleeding) and biochemically (colon levels of myeloperoxidase, malondialdehyde, chemokines and cytokines). There was significantly increased inflammatory cell infiltration into the colon associated with an increase in colon levels of cytokines and chemokines; with subsequent free radical related damage in both dextran sodium sulphate-induced colitis and 10-week-old interleukin-10−/− mice. IB-MECA protected in both models against the colitis induced inflammatory cell infiltration and damage and attenuated the increases in colon inflammatory cytokine and chemokine levels. Thus activation of the adenosine A3 receptor is effective in protecting against colitis.

We also recommend Trading Suppliers and Manufacturers of N-(3-iodobenzyl)-1-piperidinesulfonamide (cas 890593-41-6). Pls Click Website Link as below: cas 890593-41-6 suppliers

Prev:Synthesis and inhibitory activity of new benzimidazole derivatives against Burkitt’s lymphoma promotion
Next:No-carrier-added radiosynthesis of [123I]HIPDM: N,N,N′-trimethyl-N′-(2-hydroxy-3-methyl-5-[123I]iodobenzyl)-1,3-propanediamine)